Outcome of Board Meeting Held on November 12, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Board of Bharat Parenterals approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. Standalone revenue from operations fell sharply to Rs. 41.7 crore in Q2 FY26, down about 35% YoY from Rs. 64.5 crore, attributed to subdued institutional offtake, deferred export dispatches, and a one-month production break for line upgradation. Despite the revenue drop, gross margins improved significantly to 44.1% (from 35.3% YoY), driven by a favourable product mix. Standalone EBITDA stood at Rs. 2.3 crore with margin compressing to 5.6%, while PAT was Rs. 2.7 crore vs Rs. 5.5 crore in Q2 FY25. On a consolidated basis, revenue declined 10% YoY to Rs. 64.6 crore, but the company reported a narrower net loss of Rs. 8.6 crore versus Rs. 17.5 crore in Q2 FY25, primarily due to Innoxel Lifesciences' R&D spend. Management expects H2 FY26 recovery in standalone and milestone-driven revenue from Innoxel.
Near-term weakness in standalone numbers due to temporary demand and production issues may weigh on sentiment, though margin expansion signals underlying strength. Consolidated losses persist owing to Innoxel's R&D phase, but the narrowing loss trajectory and management's guidance for H2 FY26 recovery could support the stock over the medium term.